TESARO Inc (TSRO) PT Lowered to $145.00 at Cowen and Company

TESARO Inc (NASDAQ:TSRO) had its price target reduced by Cowen and Company from $155.00 to $145.00 in a research note released on Wednesday. They currently have a market perform rating on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on the company. Morgan Stanley initiated coverage on TESARO in a report on Friday, January 13th. They set an overweight rating and a $172.00 price objective for the company. Bank of America Corp upped their price objective on TESARO from $149.26 to $165.00 in a report on Thursday, January 19th. Leerink Swann restated an outperform rating and set a $152.00 price objective (up from $115.00) on shares of TESARO in a report on Monday, January 9th. Citigroup Inc restated a sell rating and set a $238.00 price objective on shares of TESARO in a report on Monday, January 30th. Finally, Wedbush restated an outperform rating and set a $139.00 price objective on shares of TESARO in a report on Wednesday, December 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the stock. TESARO currently has a consensus rating of Buy and a consensus target price of $160.27.

Shares of TESARO (NASDAQ:TSRO) opened at 152.05 on Wednesday. The stock’s market capitalization is $8.15 billion. TESARO has a one year low of $36.68 and a one year high of $192.94. The firm’s 50-day moving average price is $173.60 and its 200-day moving average price is $135.82.

Your IP Address:

In other TESARO news, VP Edward C. English sold 229 shares of the company’s stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $177.61, for a total value of $40,672.69. Following the completion of the transaction, the vice president now directly owns 625 shares of the company’s stock, valued at approximately $111,006.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Edward C. English sold 10,000 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $178.06, for a total transaction of $1,780,600.00. Following the completion of the transaction, the vice president now directly owns 5,396 shares of the company’s stock, valued at $960,811.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,793 shares of company stock valued at $2,801,638. 40.50% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. Interwest Venture Management Co. purchased a new position in TESARO during the fourth quarter worth $271,838,000. Price T Rowe Associates Inc. MD boosted its position in TESARO by 16.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 5,584,279 shares of the biopharmaceutical company’s stock worth $559,768,000 after buying an additional 776,709 shares during the last quarter. Perceptive Advisors LLC purchased a new position in TESARO during the fourth quarter worth $92,521,000. Franklin Resources Inc. boosted its position in TESARO by 21.3% in the fourth quarter. Franklin Resources Inc. now owns 3,042,844 shares of the biopharmaceutical company’s stock worth $409,207,000 after buying an additional 534,851 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in TESARO by 249.0% in the third quarter. Bank of New York Mellon Corp now owns 493,701 shares of the biopharmaceutical company’s stock worth $49,490,000 after buying an additional 352,228 shares during the last quarter. 98.48% of the stock is owned by institutional investors.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.